These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 17551678)

  • 1. The treatment of polycythaemia vera: an update in the JAK2 era.
    Finazzi G; Barbui T
    Intern Emerg Med; 2007 Mar; 2(1):13-8. PubMed ID: 17551678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk-adapted therapy in essential thrombocythemia and polycythemia vera.
    Finazzi G; Barbui T
    Blood Rev; 2005 Sep; 19(5):243-52. PubMed ID: 15963833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk stratification, staging, and treatment of patients with polycythemia vera: Italian and European collaboration on low-dose aspirin in polycythemia data.
    Finazzi G
    Semin Thromb Hemost; 2006 Apr; 32(3):276-82. PubMed ID: 16673282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How I treat patients with polycythemia vera.
    Finazzi G; Barbui T
    Blood; 2007 Jun; 109(12):5104-11. PubMed ID: 17264301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expertise-based management in essential thrombocythemia and polycythemia vera.
    Finazzi G; Barbui T
    Cancer J; 2007; 13(6):372-6. PubMed ID: 18032974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polycythemia vera.
    Landolfi R; Nicolazzi MA; Porfidia A; Di Gennaro L
    Intern Emerg Med; 2010 Oct; 5(5):375-84. PubMed ID: 20237866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence and expertise in the management of polycythemia vera and essential thrombocythemia.
    Finazzi G; Barbui T
    Leukemia; 2008 Aug; 22(8):1494-502. PubMed ID: 18596737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
    Bellucci S; Michiels JJ
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapy for polycythemia vera and essential thrombocythemia is driven by the cardiovascular risk.
    Barbui T; Finazzi G
    Semin Thromb Hemost; 2007 Jun; 33(4):321-9. PubMed ID: 17525889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Diagnosis and therapy of polycythemia vera in the era of JAK2].
    Lengfelder E
    Dtsch Med Wochenschr; 2013 Feb; 138(7):331-6. PubMed ID: 23393003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.
    Tefferi A
    Am J Hematol; 2012 Mar; 87(3):285-93. PubMed ID: 22331582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New Therapeutic Approaches in Polycythemia Vera.
    Falchi L; Newberry KJ; Verstovsek S
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl(0):S27-33. PubMed ID: 26297275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [CME: Polycythemia vera].
    Wellauer Atencio M; Goede JS
    Praxis (Bern 1994); 2019 Sep; 108(13):835-842. PubMed ID: 31571535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F.
    Stein BL; Oh ST; Berenzon D; Hobbs GS; Kremyanskaya M; Rampal RK; Abboud CN; Adler K; Heaney ML; Jabbour EJ; Komrokji RS; Moliterno AR; Ritchie EK; Rice L; Mascarenhas J; Hoffman R
    J Clin Oncol; 2015 Nov; 33(33):3953-60. PubMed ID: 26324368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Recent advances in polycythemia vera treatment].
    Edahiro Y
    Rinsho Ketsueki; 2020; 61(9):1187-1194. PubMed ID: 33162515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnosis and therapy of polycythemia vera.
    Lengfelder E; Merx K; Hehlmann R
    Semin Thromb Hemost; 2006 Apr; 32(3):267-75. PubMed ID: 16673281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
    Iványi JL; Marton E; Plander M
    Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. No evidence for JAK2(V617F) mutation in monoclonal B cells in 2 patients with polycythaemia vera and concurrent monoclonal B cell disorder.
    Stijnis C; Kroes WG; Balkassmi S; Marijt EW; van Rossum AP; Bakker E; Vlasveld LT
    Acta Haematol; 2012; 128(3):183-6. PubMed ID: 22890406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Acquired mutation of JAK2 tyrosine kinase and polycythaemia vera].
    Pargade V; Darnige L; Gaussem P
    Ann Biol Clin (Paris); 2006; 64(1):3-9. PubMed ID: 16420986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study.
    Campbell PJ; Scott LM; Buck G; Wheatley K; East CL; Marsden JT; Duffy A; Boyd EM; Bench AJ; Scott MA; Vassiliou GS; Milligan DW; Smith SR; Erber WN; Bareford D; Wilkins BS; Reilly JT; Harrison CN; Green AR; ; ;
    Lancet; 2005 Dec; 366(9501):1945-53. PubMed ID: 16325696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.